BMRA PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

BMRA ▼ -13.17% at T+5d

LONG call ✗ call lost -13.17% · α vs SPY -13.12% · entry $2.43 → $2.11

Next anchor: T+20d in 20d

Currently $2.12 · -12.76% from $2.43 entry

Entry anchored
May 27, 03:58 PM ET
via Databento tick

T+1d

-1.65%

call -1.65% · α -1.89%

$2.39

settled 8d ago

T+5d

-13.17%

call -13.17% · α -13.12%

$2.11

settled yesterday

T+20d

—

call — · α —

—

in 20d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assays, with an initial target fee of over $1.75 million. The deal monetizes existing ELISA capabilities built for its inFoods IBS platform, providing near-term revenue visibility with minimal incremental costs. For a micro-cap with an $8M market cap, a $1.75M contract is material and validates the CDMO strategy.

Key Financial Metrics

Deal Value

$1.8M

Actionable Insight

The $1.75M contract represents ~22% of BMRA's market cap, making this a material revenue catalyst for a micro-cap. Monitor for subsequent SOW execution and milestone announcements, which would confirm revenue recognition. The CDMO strategy diversifies revenue without diluting focus on inFoods IBS.

Key Facts

Master Services Agreement with confidential life sciences company for proprietary IVD assay development
Initial contract development target fee of over $1.75 million across multiple Statements of Work
Three-year initial term with automatic one-year renewals
Work performed at FDA-licensed, ISO 13485-certified Irvine facility
Revenue recognized on milestone-completion basis
Capital-light structure using existing team and equipment, minimal incremental costs expected
inFoods IBS remains primary commercial priority; CDMO is parallel revenue stream

Financial Impact

Over $1.75 million in initial development fees; material relative to $8M market cap (~22% of market cap)

revenueoperating leverage

Risk Factors

Contract partner is confidential; no visibility into creditworthiness or long-term commitment
Revenue recognition is milestone-based and contingent on SOW execution and deliverable acceptance
Forward-looking statements subject to SOW non-execution, program cancellation, or MSA termination
Micro-cap liquidity risk; $8M market cap means low trading volume and high volatility

Market Snapshot

Exchange

Nasdaq

Sector

In Vitro & In Vivo Diagnostic Substances

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3302824

4 reports for BMRA

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for BMRA — sortable, filterable
	Type				Now
Jun 4, 2026 1d ago	8-K NEUTRAL ★ 4/10	—	awaiting T+5	—	—
May 28, 2026 8d ago	Press Release BULLISH ★ 6/10	$2.43 $2.11	▼ −13.17%	▼ −13.12%	$2.12 (−12.76%)
Apr 14, 2026 7w ago	Press Release BULLISH ★ 6/10	$2.10 $2.16	▲ +2.86%	▲ +1.46%	$2.12 (+0.95%)
Apr 13, 2026 7w ago	Press Release MIXED ★ 6/10	$2.10 $2.16	▲ +2.86%	▲ +1.46%	$2.12 (+0.95%)

US Market Status

Market Closed — Opens Mon (36h 26m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access